Clonal analysis of lung and blood T cells in patients with sarcoidosis

M J Garlepp, A H Rose, J E Dench, B W S Robinson

Abstract

Background – Sarcoidosis is a disease characterised by clinical “energy” to delayed type hypersensitivity antigens and the formation of non-caseating granulomas, which frequently manifests in the lungs as a T lymphocyte/mononuclear cell alveolitis. Although there is an increased proportion of T cells in bronchoalveolar lavage (BAL) samples from these patients, and these T cells often show evidence of activation and spontaneous secretion of cytokines such as interleukin 2 (IL-2) and interferon gamma (IFNγ) – a pattern similar to delayed type hypersensitivity reactions – it is unclear whether both cytokines are produced by the majority of T cells derived from the lungs of patients with sarcoidosis or whether unique subpopulations of T cells produce each cytokine. In this study the properties of T cells cloned from BAL fluid samples of patients with sarcoidosis have been analysed.

Methods – T cells were cloned by limiting dilution using IL-2, phytohaemagglutinin, and irradiated feeder cells. Cloning efficiencies were compared and phytohaemagglutinin induced clonal production of IL-2, IFNγ, and IL-4 was determined by bioassay (IL-2 and IFNγ) or ELISA (IL-4).

Results – T cells derived from the BAL fluid of patients with sarcoidosis cloned less efficiently than those from blood of the same individuals. Lung derived clones (CD4+ or CD8+) produced IFNγ more frequently and to a higher titre than blood derived clones, whereas IL-2 production by CD4+ clones derived from BAL fluid was less than that from blood derived clones. Interestingly, IL-4 production by clones from both sites was similar. Analysis of the coproduction of IL-2, IFNγ, and IL-4 by these BAL fluid clones did not demonstrate a predominant “Th1”-like population which has been suggested to underlie delayed type hypersensitivity reactions.

Conclusions – The reduced cloning efficiency of T cells from the lung compared with the blood in sarcoidosis is consistent with, although probably more pronounced than, previous observations in normal lungs and shows that T cell hypersensitivity is not overcome in the lungs of patients with sarcoidosis. Furthermore, major differences exist between the cytokine producing potential of T cells derived from the lung and the blood in sarcoidosis, and these parallel the differences in the properties of blood and lung T cells seen in healthy individuals.

Sarcoidosis manifests in the lungs as a T lymphocyte/mononuclear phagocyte alveolitis and a granulomatous response which may result in irreversible damage to the lung parenchyma. In bronchoalveolar lavage (BAL) samples there is an increased proportion of lymphocytes and, in active disease, usually an increase in the ratio of CD4+ to CD8+ T cells. T cells associated with the granulomas in lung biopsies and BAL samples often express interleukin 2 receptors (IL-2R) and other markers of activation such as HLA-DR. Furthermore, these T cells in BAL fluid spontaneously secrete cytokines such as IL-2, interferon gamma (IFNγ), and monocyte chemotactic factor. These data suggest an ongoing T cell response. The stimulating agent or antigen is unknown, but the cytokines released are thought to facilitate recruitment of mononuclear cells and granuloma formation, and it seems likely that CD4+ T cells are intimately involved in this process.

Murine CD4+ T cell clones have been divided into “Th1” cells which produce IL-2, IFNγ, and lymphotoksin and mediate delayed type hypersensitivity responses, and “Th2” cells which produce IL-4, IL-5, and IL-6 and provide help for B cell differentiation and immunoglobulin production. Although this division is yet to be conclusively demonstrated for human T cells, some evidence has accumulated to support the existence of such subpopulations.

The profile of cytokines produced spontaneously by lung T cells from patients with sarcoidosis – that is, IL-2, IFNγ – and the characteristic presence of granulomas reminiscent of foci of delayed type hypersensitivity reactivity, suggest that the CD4+ cells infiltrating sarcoid lungs may be of the Th1 type. Previous studies of T cells obtained from the BAL fluid and blood of patients with pulmonary sarcoidosis have largely concentrated on whole populations rather than individual T cell responses. It is, however, unknown whether separate populations of T cells produce IFNγ and IL-2 or whether both cytokines are produced by a single population of T
cells. Further, it is unclear whether most of the T cells in the lungs of patients with sarcoidosis are capable of producing these cytokines, or whether a relatively minor subpopulation is responsible for their secretion.

We have recently shown major differences in the cytokine producing capacity of T cell clones derived from healthy lungs compared to those derived from peripheral blood of the same subjects. In the work reported here we compare the properties of T cell clones from the lungs of patients with sarcoidosis with those derived from autologous blood.

**Methods**

**STUDY POPULATION**

Nine patients who fulfilled standard criteria for the diagnosis of sarcoidosis were studied. Clinical and physiological data for each patient at the time of lavage are presented in table 1. All patients were non-smokers. T cell clones were also derived from nine healthy volunteers (eight men, one woman; six non-smokers, two ex-smokers, and one smoker) of mean (SD) age 54 (10) years in an overlapping study. Data on these subjects have been published previously save for those on IL-4 production by CD8+ clones which are presented here. The study was approved by the Human Rights Committee of the University of Western Australia.

**PREPARATION OF BAL FLUID AND PERIPHERAL BLOOD CELLS**

Bronchoalveolar lavage was performed as previously described. Briefly, the bronchoscope was passed transorally and wedged in a subsegmental bronchus. Six 50 ml aliquots of warm (37°C) saline solution were infused into the lung and recovered immediately into disposable sterile polycarbonate bottles. The first aliquot was analysed separately and the remaining five were pooled and used as the “alveolar cell” sample. The volume and appearance of this sample were recorded and the cells were concentrated by centrifugation at 400 g for seven minutes. Cell viability was determined by trypan blue exclusion and differential cell counts were performed on 400 cells stained with May-Grunwald-Giemsa stain (105 cells per slide). Blood from each patient was collected in heparinised tubes at the time of lavage and mononuclear leukocytes isolated using Ficoll-Paque (Pharmacia Fine Chemicals, Uppsala, Sweden) density centrifugation.

**T CELL CLONING BY LIMITING DILUTION**

T cells were purified from BAL fluid and blood samples by adherence and rosetting with sheep erythrocytes and seeded into round bottomed 96 well microtest plates (Nunc, Roskilde, Denmark) at densities of 0.25, 0.5, 1, 2, 4, 8, and 16 cells per well in a total volume of 200 µl RPMI-1640 (Flow Laboratories, North Ryde, Australia) containing 15% human AB serum, 1 µg/ml phytohaemagglutinin (Wellcome, UK), 100 U/ml IL-2 (Cetus, Emeryville, California, USA), and 105 irradiated feeder cells. Feeder cells were either irradiated (5000 rad) freshly prepared autologous or allogeneic blood mononuclear cells or human spleen cells (3000 rad) which had been stored, cryopreserved, and cultured overnight in phytohaemagglutinin before use. Fresh media and feeder cells were added at day 7 and positive wells were scored on day 12. The fraction of non-responding wells was plotted against the number of cells seeded per well on a semilogarithmic plot and precursor frequencies were determined according to the zero order term of the Poisson probability distribution. Positive wells were expanded from plates showing T

---

**Table 1 Clinical, physiological, and bronchoalveolar lavage data for individual patients with sarcoidosis**

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Sex</th>
<th>Age (years)</th>
<th>Disease duration (years)</th>
<th>Treatment*</th>
<th>Chest radiography†</th>
<th>TLCO</th>
<th>Ga+</th>
<th>BAI fluid differential count (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1784</td>
<td>F</td>
<td>50</td>
<td>16</td>
<td>Nil</td>
<td>N</td>
<td>113</td>
<td>4-2</td>
<td>88-0</td>
</tr>
<tr>
<td>1744</td>
<td>F</td>
<td>29</td>
<td>0.3</td>
<td>Nil</td>
<td>II</td>
<td>110</td>
<td>3-4</td>
<td>43-8, 52-6</td>
</tr>
<tr>
<td>1580</td>
<td>M</td>
<td>64</td>
<td>1</td>
<td>Nil</td>
<td>I</td>
<td>76</td>
<td>4-2</td>
<td>80-2</td>
</tr>
<tr>
<td>1777</td>
<td>F</td>
<td>31</td>
<td>0.1</td>
<td>Nil</td>
<td>I</td>
<td>84</td>
<td>3-6</td>
<td>68-0</td>
</tr>
<tr>
<td>1555</td>
<td>F</td>
<td>68</td>
<td>5</td>
<td>Nil</td>
<td>III</td>
<td>64</td>
<td>5-2</td>
<td>56-5</td>
</tr>
<tr>
<td>1705</td>
<td>F</td>
<td>53</td>
<td>10</td>
<td>Nil</td>
<td>I</td>
<td>78</td>
<td>4-5</td>
<td>68-3</td>
</tr>
<tr>
<td>1745</td>
<td>F</td>
<td>50</td>
<td>8</td>
<td>Nil</td>
<td>III</td>
<td>68</td>
<td>7-2</td>
<td>85-1</td>
</tr>
<tr>
<td>1793</td>
<td>M</td>
<td>35</td>
<td>6</td>
<td>Nil</td>
<td>III</td>
<td>80</td>
<td>3-2</td>
<td>88-6</td>
</tr>
<tr>
<td>1867</td>
<td>F</td>
<td>42</td>
<td>6</td>
<td>Nil</td>
<td>III</td>
<td>85</td>
<td>3-2</td>
<td>32-6</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td></td>
<td>84.9</td>
<td>(16.9)</td>
<td></td>
<td></td>
<td>100</td>
<td>4-2</td>
<td>67-9</td>
</tr>
<tr>
<td>Normal (SD)</td>
<td></td>
<td>84.9</td>
<td>(16.9)</td>
<td></td>
<td></td>
<td>100</td>
<td>4-2</td>
<td>79.7</td>
</tr>
</tbody>
</table>

*TLCO = single breath carbon monoxide diffusing capacity, expressed as % of predicted value; M = macrophages; L = lymphocytes; N = neutrophils; E = eosinophils; NM = not measured.
* Nil = no treatment at time of entry into study, pred = prednisolone 7.5 mg/day.
* Type I (I) = hilar nodes only; type II (II) = hilar nodes + parenchymal shadowing; type III (III) = parenchymal shadowing only; N = normal.
* Gallium lung scans: N = nodal uptake; N = no nodal uptake; L = increased parenchymal uptake; L = no increased parenchymal uptake.
* Data obtained from previous studies carried out in this laboratory on normal subjects.14
Clonal analysis of sarcoid T cells

Statistical analysis

Statistical analysis

Results

Cellular content of BAL fluid and blood

The total cell yield and the volume of lavage fluid recovered from patients with sarcoidosis were similar to those obtained by lavage of normal subjects (data not shown). The percentage of lymphocytes in the BAL fluid varied from 10% to 64%. The percentage of CD4+ T cells in the BAL fluid from patients with sarcoidosis varied from 50% to 100%, compared with 33–52% in the peripheral blood.

Cloning efficiency

T cells derived from BAL fluid of patients with sarcoidosis cloned far less efficiently than those derived from the blood (p<0.05, Wilcoxon rank sum). In all cases the T cell precursor frequency in BAL samples was less than that in the blood of the same subject (fig 1). Blood derived T cells from patients with sarcoidosis were as readily clonable as those from healthy individuals (median precursor frequency 6.2±2.0 with 6.3 for normals). T cells from the BAL fluid samples of patients with sarcoidosis were less readily clonable than those from the BAL fluid of healthy subjects using identical methods and performed during the same time period (median precursor frequency for BAL samples from sarcoid patients 47.3±20.5 for normals).

Surface phenotype

The number of CD4+ clones derived from BAL fluid samples from patients with sarcoidosis ranged from five to 38 (mean 17.5), and from the blood of patients with sarcoidosis the range was four to 59 (mean 22.5). CD8+ clones were less common, the range for BAL fluid being one to 16 (mean four) and for blood one to 15 (mean six). A total of 161 BAL fluid derived and 209 blood derived CD4+ clones were analysed along with 37 BAL fluid derived and 54 blood derived CD8+ clones. The mean proportions of CD4+ and CD8+ clones generated from BAL fluid samples from patients with sarcoidosis did not differ signi-

Figure 1 Cloning frequencies for T cells cloned from BAL fluid and blood of patients with sarcoidosis. The data are plotted as the number of starting cells which yield a single T cell clone (1/n).
significantly from the proportions present in the starting populations, although CD4+ T cells were more readily clonable than CD8+ cells from the blood of patients with sarcoidosis (fig 2).

CYTOKINE SYNTHESIS BY CD4+ CLONES
As the cytokine producing potentials of CD4+ and CD8+ cells are known to differ, and in view of potential heterogeneity within the CD4+ population, CD4+ and CD8+ clones were analysed separately. Eight of the nine subjects yielded sufficient CD4+ clones to allow comparison of the properties of clones derived from BAL fluid and blood within individuals. In seven subjects IFNγ production by clones derived from BAL fluid was greater than that by blood derived clones (p < 0.01), and in one the difference was not statistically significant (fig 3A). IL-2 production was less in clones derived from BAL fluid than in those derived from blood (p < 0.02) in each of five subjects and not significantly different in three (fig 3B). The pooled data clearly indicated that CD4+ clones derived from BAL fluid of patients with sarcoidosis produced significantly more IFNγ (p < 0.0005) and significantly less IL-2 (p < 0.0005) than those derived from blood of patients with sarcoidosis (data not shown). By contrast, production of IL-4 by CD4+ clones derived from blood and BAL fluid differed in only one subject (data not shown).

IL-2 AND IFNγ SYNTHESIS BY CD8+ CLONES
Insufficient CD8+ clones were available from each patient to allow meaningful individual analyses so only pooled data were compared (fig 4). Clones derived from BAL fluid produced higher concentrations of IFNγ than those from blood (p < 0.02). The distributions of IL-2 (fig 4) and IL-4 (data not shown) concentrations were not significantly different.

Discussion
Despite the apparent heightened “activation” of T cells derived from the BAL fluid of patients with sarcoidosis in comparison with those from normal individuals and from autologous blood, this study shows that the T cells have a reduced response to T cell mitogens under the cloning conditions used here. This is consistent with the observation of reduced responses of T cells from BAL fluid of patients with sarcoidosis to common recall antigens such as purified protein derivative and Candida antigen. The reduced cloning efficiency of T cells derived from BAL fluid, compared with blood, of healthy individuals is thus not overcome in the lungs of patients with sarcoidosis. This

**Figure 2** Phenotypes of starting T cell populations and resultant clones derived from BAL fluid and blood of patients with sarcoidosis (graphs show mean ± SE).
Clonal analysis of sarcoid T cells

**Figure 3**  
(A) IFNγ production by T cell clones derived from BAL fluid or blood of patients with sarcoidosis. Comparisons between BAL fluid and blood derived clones were made using the Wilcoxon rank sum test. Clones derived from BAL fluid produced more IFNγ than those from blood \((p<0.01)\) in all subjects except 1867.  
(B) IL-2 production by T cell clones derived from BAL fluid or blood of patients with sarcoidosis. Blood derived clones produced more IL-2 than those from BAL fluid \((p<0.02)\) in all subjects except 1555, 1745, and 1867.
Figure 4  (A) IFNγ and (B) IL-2 production by CD8+ clones derived from patients with sarcoidosis.

Figure 5  Distribution of CD4+ clones from BAL fluid or blood of patients with sarcoidosis according to their production of IFNγ and IL-2 (BAL fluid, n = 145; blood, n = 180) or IFNγ and IL-4 (BAL fluid, n = 98; blood, n = 97). Some data points are superimposed.
Clonal analysis of sarcoid T cells

Provides further confirmation that the lymphocyte accumulation in the lung in sarcoidosis represents part of a pathophysiological process and not merely a "leakage" of blood lymphocytes into the lung. Whether this reduced clonability is acquired before entering the lung or under the immunosuppressive influence of the lung milieu is unknown. Interestingly, it appears that T lymphocytes derived from the BAL fluid of patients with sarcoidosis clone even less efficiently than those from normal BAL fluid, even though the cloning efficiencies of T cells derived from the blood of both subject groups were similar. This reduction in proliferative response and clone precursor frequency of lung T cells may be due to an amplification of the suppressive effect in the lung in sarcoidosis. The number and activity of suppressive macrophages in the alveoli are increased in sarcoidosis. Alternatively, post-activated lymphocytes are less clonable. There is evidence for T cell receptor downregulation in sarcoidosis, so the reduced cloning efficiency may reflect local T cell activation or accumulation of activated T cells in the lungs. Whether the T cells in the lung are in a state of partial anergy or are committed to a path towards cell death is also unknown. Data from Becker et al indicating some responsiveness to anti-CD3 and IL-2, in healthy lung T cells at least, are consistent with the former.

T cells freshly isolated from the lavage fluid of patients with sarcoidosis spontaneously secrete IFNγ and those derived from patients with very active disease secrete IL-2. The data in the present study which show that the majority of both CD4+ and CD8+ lung clones are intrinsically capable of producing IFNγ, and that a much smaller proportion produce IL-2, may be a reflection of the less severe level of inflammation of most of the patients studied or, more likely, they may indicate that IFNγ is produced by most lung T cells in sarcoidosis whereas IL-2, when produced, is produced by a smaller proportion of these cells. This is supported by the observation that granuloma associated T cells predominantly produce IFNγ rather than IL-2. Conversely, a greater proportion of CD4+ blood derived clones produced IL-2 than IFNγ. These data are consistent with our observations in healthy subjects, suggesting that in both patients with sarcoidosis and normal individuals the lung milieu may exert a modulating influence on recruited T cells in favour of IFNγ production or, alternatively, T cells of this phenotype may be selectively recruited from the blood to the lung.

T cell dichotomy has been shown in several human immunological responses and diseases with an immunological basis. In tuberculosis leprosy Th1-like cells predominate, whereas Th2-like cells are found in the lepromatous form, and in cutaneous responses to purified protein derivative Th1 cells are found, while in local atopic allergic responses Th2 cells predominate. We hypothesised that a predominance of Th1-like T cell clones would be derived from the BAL fluid of sarcoidosis patients. The majority of CD4+ clones were neither Th1 nor Th2 in phenotype since they

Figure 6 Distribution of CD8+ clones according to their production of IFNγ and IL-4. The numbers of clones analysed were: normal BAL fluid, n=38; normal blood, n=33; sarcoid BAL fluid, n=29; sarcoid blood, n=32.
were capable of producing both IL-4 and IFNγ. This is consistent with previous reports in which T cell clones have been stimulated with mitogens. Amongst clones derived from BAL fluid there was a clear population (28%) which produced IFNγ without IL-4, and a minority of BAL fluid of healthy lungs, although reduced proliferative capacity seems to be more pronounced in the lungs of patients with sarcoidosis, suggesting either suppression or anergy. Major differences also exist in the cytokine producing potential of T cells derived from the lung and the blood, and again these parallel the differences in the properties of blood and lung T cells seen in healthy individuals.

In summary, this study has confirmed that T lymphocytes derived from the lungs of patients with pulmonary sarcoidosis are less readily clonable than those from autologous peripheral blood. These data are consistent with the properties of T cells derived from BAL fluid and from sarcoid lung. CD8+ T cells and CD4+ T cells both provided no evidence for a shift to Th1 phenotype was seen.

"Comparison of cytokine production by T cell clones derived from sarcoid and normal populations" Table 2

<table>
<thead>
<tr>
<th>IFNγ</th>
<th>IL-2</th>
<th>IL-4</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>Median</td>
</tr>
<tr>
<td>CD4+ BAL fluid</td>
<td>153</td>
<td>32</td>
</tr>
<tr>
<td>N</td>
<td>61</td>
<td>32</td>
</tr>
<tr>
<td>P</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>CD4+ blood</td>
<td>198</td>
<td>2</td>
</tr>
<tr>
<td>N</td>
<td>77</td>
<td>4</td>
</tr>
<tr>
<td>P</td>
<td>0.02</td>
<td>NS</td>
</tr>
<tr>
<td>CD8+ BAL fluid</td>
<td>34</td>
<td>40</td>
</tr>
<tr>
<td>N</td>
<td>50</td>
<td>12</td>
</tr>
<tr>
<td>P</td>
<td>0.01</td>
<td>&lt;0.005</td>
</tr>
<tr>
<td>CD8+ blood</td>
<td>52</td>
<td>16</td>
</tr>
<tr>
<td>N</td>
<td>42</td>
<td>64</td>
</tr>
<tr>
<td>P</td>
<td>&lt;0.005</td>
<td>0.01</td>
</tr>
</tbody>
</table>

S = sarcoidosis, N = normal, p = value derived by comparing ranges of cytokine concentrations using the Wilcoxon rank sum test.

Cytokine concentrations are expressed in the same units as described in Methods section. Data on normal individuals were taken from our previously published work and from CD8+ data presented in this paper.

Median values are shown since these reflect the wide distribution of cytokine concentrations (see figs 3–6 for concentration ranges).

This work was supported by a grant from the National Health and Medical Research Council of Australia. We thank Ms Margaret Baron-Hay for her assistance with the IL-2 bioassay.

Clonal analysis of sarcoid T cells


